0001493152-24-005944.txt : 20240212 0001493152-24-005944.hdr.sgml : 20240212 20240212213012 ACCESSION NUMBER: 0001493152-24-005944 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240211 FILED AS OF DATE: 20240212 DATE AS OF CHANGE: 20240212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Samuel George A. III CENTRAL INDEX KEY: 0001878732 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12830 FILM NUMBER: 24622330 MAIL ADDRESS: STREET 1: C/O LINEAGE CELL THERAPEUTICS, INC. STREET 2: 2173 SALK AVENUE, SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lineage Cell Therapeutics, Inc. CENTRAL INDEX KEY: 0000876343 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943127919 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 5105213390 MAIL ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 FORMER COMPANY: FORMER CONFORMED NAME: BIOTIME INC DATE OF NAME CHANGE: 19930328 4 1 ownership.xml X0508 4 2024-02-11 0 0000876343 Lineage Cell Therapeutics, Inc. LCTX 0001878732 Samuel George A. III 2173 SALK AVENUE, SUITE 200 CARLSBAD CA 92008 0 1 0 0 General Counsel/Secretary 0 Common Shares, no par value 2024-02-11 4 M 0 6076 A 9674 D Common Shares, no par value 2024-02-11 4 F 0 2490 1.08 D 7184 D Restricted Stock Units 0.00 2024-02-11 4 M 0 6076 0.00 D Common Shares 6076 12151 D Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. /s/ George A. Samuel III 2024-02-12